The present invention relates to a device, a kit and a high-sensitivity method for detecting low levels of the T4 hormone in urine during pregnancy, using a competitive colorimetric lateral-flow assay with monoclonal antibodies.The invention thereby allows self-detection of this pathology from the first weeks of pregnancy, by means of a simple test for use at home, as well as the control of the levels of this hormone throughout the pregnancy, in an easy, simple and non-invasive manner.
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/531 - Production de matériaux de tests immunochimiques
2.
MICROENCAPSULATED NATURAL PRESERVATIVE AND ANTIOXIDANT FOR FATTY FOODS, WITH WALNUT HUSK AND WALNUT TREE LEAF EXTRACT
The invention relates to a method for producing a microencapsulated natural preservative and antioxidant that comprises a walnut tree leaf and husk extract, the obtained preservative, and the use thereof for preserving foods containing fats. The natural preservative is specifically a hydroalcoholic walnut husk and/or walnut tree leaf extract, which is microencapsulated with a hydrosoluble polymer (HSP), such as maltodextrin or inulin, and wherein the microparticle comprises channelling agents, which are liposoluble polymers (LSP), such as soy protein isolate or Capsul. These microparticles provide controlled release action of the antioxidant and preservative extract, which allows action to take place over time.
INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT (France)
INSTITUT NATIONAL DES SCIENCES ET INDUSTRIES DU VIVANT ET DE L'ENVIRONNEMENT (France)
UNIVERSITE DE VERSAILLES SAINT-QUENTIN-EN-YVELINES (France)
ÉCOLE NATIONALE VETERINAIRE D'ALFORT (France)
UNIVERSIDAD ANDRES BELLO (Chili)
Inventeur(s)
Barrey, Eric
Fitzpatrick Marin, Christopher Shawn
Pollet, Sophie
Delmas, Bernard
Meunier, Nicolas
Da Costa, Bruno
Éléouët, Jean François
Le Poder, Sophie
Burzio Menendez, Verónica Andrea
Abrégé
The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.
The present disclosure relates to the generation of food grade sugar modified 1-MCP nanobubbles ranging in size from 50 to 600 nm. These nanobubbles have a high degree of stability while in aqueous solution and can inhibit the action of ethylene in different biological processes. In addition, they can reduce the action of ethylene in plant metabolism, making the plant less susceptible to water stress, low temperature stress, and stress from soil conditions, among others. This disclosure also relates to the method of preparing sugar modified 1-MCP nanobubbles, their different uses and applications.
difficiledifficiledifficile (R-CDI) in a subject. A method for the treatment of CDI and for the treatment of R-CDI, and for reduction of the risk of developing R-CDI in a subject in need thereof, which comprises the administration of said pharmaceutical composition. A method for the treatment or prevention of a first CDI in a subject in need thereof, which comprises the administration of said pharmaceutical composition to a subject.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p.ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
A61K 38/14 - Peptides contenant des radicaux saccharide; Leurs dérivés
6.
AGAROPHYTON CHILENSIS EXTRACT, RICH IN FREE FATTY ACIDS, AS A NUTRACEUTICAL OR NUTRITIONAL SUPPLEMENT, SUITABLE FOR MODULATING PPAR# ACTIVITY
Agarophyton chilensis extract, enriched with free fatty acids and PPARγ modulators, comprising palmitic acid, stearic acid, myristic acid, oleic acid, and 8-hydroxyeicosatetraenoic acid (8-HETE). Method for obtaining the extract. Nutraceutical composition, comprising the extract enriched with free fatty acids and PPARγ modulators, wherein said extract is useful for treating or preventing health problems, which require neuroprotection, wherein said neuroprotection involves activation of PPARγ receptors.
A61K 36/04 - Rhodophycota ou rhodophyta (algues rouges), p.ex. Porphyra
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61K 31/20 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique
7.
ANTIPROLIFERATIVE EFFECT OF AGAROPHYTON CHILENSIS EXTRACT IN PROSTATE CANCER
The invention relates to a pharmaceutical composition of an extract of Agarophyton chilensis, with antiproliferative effect in prostate cancer, comprising
The invention relates to a pharmaceutical composition of an extract of Agarophyton chilensis, with antiproliferative effect in prostate cancer, comprising
(a) 0.1 to 90% of an oleoresin of Agarophyton chilensis, with the following major components: palmitic acid, arachidonic acid, oleic acid, stearic acid, meristic acid, linoleic acid; and
The invention relates to a pharmaceutical composition of an extract of Agarophyton chilensis, with antiproliferative effect in prostate cancer, comprising
(a) 0.1 to 90% of an oleoresin of Agarophyton chilensis, with the following major components: palmitic acid, arachidonic acid, oleic acid, stearic acid, meristic acid, linoleic acid; and
(b) 10 to 99.9% excipients and formulation aids for different pharmaceutical forms. And its use to prepare a drug for the treatment or prevention of prostate cancer and other hyperproliferative states of prostate tissue cells.
A61K 36/04 - Rhodophycota ou rhodophyta (algues rouges), p.ex. Porphyra
A61K 31/20 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique
A61K 31/201 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique ayant une ou deux doubles liaisons, p.ex. acides oléique ou linoléique
A61K 31/202 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p.ex. acide linolénique
The present invention provides new primers and mixtures thereof for detecting the presence of the human coronavirus SARS-CoV-2 genome in nasopharyngeal or saliva samples, thus allowing detection thereof with high specificity, ease of handling, fast and easy reading, without needing to extract RNA from the samples. The present invention also includes a kit that uses RT-LAMP for a rapid test, thus obtaining a final reading indicated by a colorimetric change or fluorescence emission when the presence of genetic material from SARS-CoV-2 is detected.
C12Q 1/6888 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
9.
F. nucleatum; use in the treatment of diseases associated with this pathogen
A sequential or cascading predictive control method is provided, including first solving a cost function and then a second cost function for two or more control objectives. The method includes
separating the cost function into at least two or more cost functions, depending on the number of defined control objectives.
The method additionally includes controlling a first variable with a unitary cost function, a single term or nature of the control objectives.
The method also includes determining the possible states that minimize the cost of the first objective to be controlled.
Considering only the options given through this determination, a second variable is controlled with a cost function that minimizes the cost function thereof.
G01R 31/367 - Logiciels à cet effet, p.ex. pour le test des batteries en utilisant une modélisation ou des tables de correspondance
G05B 13/04 - Systèmes de commande adaptatifs, c. à d. systèmes se réglant eux-mêmes automatiquement pour obtenir un rendement optimal suivant un critère prédéterminé électriques impliquant l'usage de modèles ou de simulateurs
H02P 23/14 - Estimation ou adaptation des paramètres des moteurs, p.ex. constante de temps du rotor, flux, vitesse, courant ou tension
H02P 27/06 - Dispositions ou procédés pour la commande de moteurs à courant alternatif caractérisés par le type de tension d'alimentation utilisant une tension d’alimentation à fréquence variable, p.ex. tension d’alimentation d’onduleurs ou de convertisseurs utilisant des convertisseurs de courant continu en courant alternatif ou des onduleurs
11.
AGAROPHYTON CHILENSIS EXTRACT, RICH IN FREE FATTY ACIDS, AS A NUTRACEUTICAL OR NUTRITIONAL SUPPLEMENT, SUITABLE FOR MODULATING PPARϒ ACTIVITY
An Agarophyton chilensis extract, enriched with free fatty acids and PPARγ modulators, which comprises palmitic acid, stearic acid, myristic acid, oleic acid and 8-hydroxyeicosatetraenoic acid (8-HETE). A method for obtaining the extract. A nutraceutical composition which comprises the extract enriched with free fatty acids and PPARγ modulators, wherein said extract is suitable for treating or preventing health conditions that require neuroprotection, said neuroprotection involving the activation of PPARγ receptors.
A61K 36/04 - Rhodophycota ou rhodophyta (algues rouges), p.ex. Porphyra
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
12.
ANTIPROLIFERATIVE EFFECT OF AGAROPHYTON CHILENSIS EXTRACT IN PROSTATE CANCER
Agarophyton chilensisAgarophyton chilensisAgarophyton chilensis oleoresin with the main components of palmitic acid, arachidonic acid, oleic acid, stearic acid, myristic acid, linoleic acid; and b) from 10% to 99.9% of formulation excipients and auxiliaries for different pharmaceutical forms. The invention also relates to the use thereof for preparing a drug for treating or preventing prostate cancer and other hyperproliferative states of prostate tissue cells.
The present disclosure relates to the generation of food grade sugar modified 1-MCP nanobubbles ranging in size from 50 to 600 nm. These nanobubbles have a high degree of stability while in aqueous solution and can inhibit the action of ethylene in different biological processes. In addition, they can reduce the action of ethylene in plant metabolism, making the plant less susceptible to water stress, low temperature stress, and stress from soil conditions, among others. This disclosure also relates to the method of preparing sugar modified 1-MCP nanobubbles, their different uses and applications.
The invention relates to a device and method for the culture of red algae spores, which comprises: a structure with U-shaped guide frames that supports a system of frames supporting a substrate for the settlement of spores in an inclined position, which is handled from outside the water by means of a lever connected to two horizontal bars that support the guide frames; and a spore resuspension system comprising tubes in which water, air and spores circulate, to make use of non-settled spores. The invention also relates to culture in inclined frames (supplanting the paradigm of horizontal culture, used until now because of the lack of mobility of the red algae spores) and to the controlled use of the spore resuspension system, and prevents contamination caused by handling of the culture.
C12N 1/12 - Algues unicellulaires; Leurs milieux de culture
A01K 63/00 - Récipients pour poissons vivants, p.ex. aquariums; Terrariums
15.
FUNCTIONALIZED SILICA NANOPARTICLES AND MICROPARTICLES WITH AT LEAST ONE GUANIDINE GROUP; METHOD OF PREPARATION; METHOD TO REMOVE ANIONS FROM EFFLUENTS; AND USE OF SAID PARTICLES
EL INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE MONTERREY (Mexique)
FUNDACIÓN LEITAT CHILE (Chili)
Inventeur(s)
Arismendi Macuer, Marlene Natalia
González Nilo, Fernando Danilo
Valencia Gallegos, Jesús Angel
Garcia Fernandez, Maria De Los Angeles
Faccini, Mirko
Abrégé
2 2 nanoparticles and microparticles that have been functionalized on their surface with guanidine and bisguanidine groups. Additionally, the preparation method of said modified particles is disclosed. In addition, the present invention refers to a method and device for the removal of anions from drinking water and industrial waters comprising contacting the water with the functionalized nanoparticles and microparticles.
C02F 1/28 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par absorption ou adsorption
B01J 20/10 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant de la silice ou un silicate
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
Recurrent C. difficile infections are the major cause of death due to C. difficile, which is the causative agent of approximately 20% of antibiotic-associated diarrheas. Conventional treatments for C. difficile infections are not capable of eliminating the rates of recurrence, which occurs in 20-30% of the cases and may be repetitive, the probability of death being greater in each cycle. Until now, the persistence mechanisms of C. difficile for producing recurrence conditions were unknown. In the present invention, we describe the mechanism by which C. difficile spores persist, and a method of treatment with a pharmacological composition based on an antibiotic and nystatin for preventing recurrent C. difficile infections. The route of administration of nystatin is also protected (i.e., oral, intraperitoneal).
C07K 14/33 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Clostridium (G)
difficiledifficiledifficiledifficiledifficile difficile difficile infections. The route of administration of nystatin is also protected (i.e., oral, intraperitoneal).
C07K 14/33 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Clostridium (G)
H02M 7/00 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continu; Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif
H02M 7/5387 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif sans possibilité de réversibilité par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs, p.ex. onduleurs à impulsions à un seul commutateur dans une configuration en pont
19.
METHOD FOR SEQUENTIAL PREDICTIVE CONTROL, FIRST SOLVING A COST FUNCTION AND SUBSEQUENTLY A SECOND COST FUNCTION FOR TWO OR MORE CONTROL OBJECTIVES
The invention describes a predictive control method for rectifiers/inverters, which defines mathematical models that represent a load/network and a converter/inverter, to then define control objectives for the load/network and the converter/inverter. For both cases, single or multiple cost functions are defined, depending on the nature of the control objectives. If the control objectives are the same, a single, variable cost function is used; if not, there are as many cost functions as control objectives. Subsequently, the possible states that minimise the cost function associated with the load/network model are evaluated and determined, and said states are used to minimse the cost function associated with the converter/inverter model. The process of evaluating objective functions is repeated with redundancies.
H02P 21/14 - Estimation ou adaptation des paramètres des machines, p.ex. flux, courant ou tension
H02P 23/14 - Estimation ou adaptation des paramètres des moteurs, p.ex. constante de temps du rotor, flux, vitesse, courant ou tension
H02P 27/06 - Dispositions ou procédés pour la commande de moteurs à courant alternatif caractérisés par le type de tension d'alimentation utilisant une tension d’alimentation à fréquence variable, p.ex. tension d’alimentation d’onduleurs ou de convertisseurs utilisant des convertisseurs de courant continu en courant alternatif ou des onduleurs
20.
Controlled release system including a gas or volatile encapsulated in a polymeric support and a matrix system, a method of preparing the system, and their use
A controlled release system includes a polymeric support, wherein the polymeric support is biodegradable; a polymeric matrix, wherein the polymeric matrix includes polyhydroalkanoate; and encapsulated gases or volatiles; and a controlled release system includes a polymeric support; a polymeric matrix, wherein the polymeric matrix includes (poly-3-hydroxybutyrate-co-3-hydroxyvalerate) and poly (ε-caprolactone); and encapsulated gases or volatiles.
A01N 27/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des hydrocarbures
A01N 31/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques de l'oxygène ou du soufre l'atome d'oxygène ou de soufre étant lié à une chaîne latérale aliphatique d'un système cyclique carbocyclique
A61K 9/48 - Préparations en capsules, p.ex. de gélatine, de chocolat
A01N 25/22 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'application; Substances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des ingrédients stabilisant les ingrédients actifs
A01N 31/06 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques de l'oxygène ou du soufre l'atome d'oxygène ou de soufre étant lié directement à un système cyclique cycloaliphatique
21.
PHARMACEUTICAL COMPOSITION BASED ON BACTERIOPHAGES AGAINST F. NUCLEATUM; USE IN THE TREATMENT OF DISEASES ASSOCIATED WITH THIS PATHOGEN
A pharmaceutical composition comprising: a) an effective amount of one or more lytic bacteriophages specific against Fusobacterium nucleatum selected from FnpФ02-14, FnpФ11 and FnnФ107 or mixtures of them; and b) one or more pharmaceutically acceptable carrier and/or excipients. Method for preventing and/or treating diseases associated with Fusobacterium nucleatum and the use of the pharmaceutical composition for treating a disease associated with Fusobacterium nucleatum of the oral cavity such as periodontal disease, among others.
The invention relates to a multilevel converter that operates with fewer components, reducing costs, losses, size and weight, thereby allowing volume to be reduced and making the control and transformation of electrical energy more accessible. The multilevel converter comprises at least one basic cell formed by: a) a first power switch that connects the positive bus to the at least one basic cell and to at least one other basic cell, the cells being connected together in cascade, and/or a basic cell and a continuous voltage source; b) a second power switch that connects the negative bus to the at least one basic cell and to at least one other basic cell, the cells being connected together in cascade, and/or a basic cell and the continuous voltage source from a); and c) a capacitor with a third power switch, both connected together in series and connected to the positive and negative buses.
H02M 7/00 - Transformation d'une puissance d'entrée en courant alternatif en une puissance de sortie en courant continu; Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant alternatif
23.
CHEMICAL PREPARATION OF LITHIUM SULFIDE NANOPARTICLES
Method for chemical preparation of lithium sulfide nanoparticles (Li2S NPs) comprising: a) Mixing an aqueous solution of a lithium salt with an aqueous solution of a compound such as thiol in a citrate-borax buffer solution at pH 8.0. 5 b) Incubating the solution obtained in stage (a) at a temperature between 50- 170°C in an aerobic or anaerobic atmosphere during 1-8 hours, until lithium sulfide nanoparticles are formed. c) Reducing incubation temperature of stage (b) to 2-10°C during 2-6 hours. d) Stopping the reaction once stage (c) incubation time has passed. NPs created by means of the proposed method have a particle size between 15 and 30 nm and an absorbance pattern with maximum absorbance between 400 and 410 nm. Use of NPs obtained by the proposed method in the manufacture of batteries, rechargeable batteries, supercapacitors and energy storage devices.
The invention relates to a method for the chemical preparation of fluorescent, semiconductive nanoparticles (NPs) of copper sulphide, comprising: a) preparing a solution of a copper salt together with a solution of a reducing agent which will be the source of the sulphide, and subsequently mixing said two solutions; b) adding, to the solution produced in (a), a buffer solution with a concentration of between 10 and 50 mM and a pH of between 7 and 10, by means of stirring; c) incubating the solution produced in (b), at a temperature of between 28°C and 100°C, for between 18 and 24 hours of incubation until a yellow-gold solution is formed, which is indicative of the generation of NPs of copper sulphide; and d) stopping the reaction at a temperature of between 4°C and 25 °C.
C09K 11/58 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du cuivre, de l'argent ou de l'or
The invention relates to a method for the synthesis of fluorescent, semiconductive nanoparticles (NPs) of cadmium sulphide (CdS), comprising: a) mixing i. a thiol as a source of sulphur and as a covering compound; ii. a cadmium salt; iii. a compound containing or generating a source of phosphate; b) adding a buffer solution to the mixture obtained in step (a), at a pH of between 7 and 10, in the presence or absence of oxygen and at a temperature of between 15 and 80°C; c) incubating the solution produced in b) at a temperature of between 15 and 80°C, for an incubation period of between 1 and 9 days, until fluorescence is obtained; and d) evaluating the fluorescence of the NPs of CdS, exposing them to a UV transilluminator (at 365 nm).
C09K 11/54 - Substances luminescentes, p.ex. électroluminescentes, chimiluminescentes contenant des substances inorganiques luminescentes contenant du zinc ou du cadmium
The invention relates to a microbiological method for the production of fluorescent, semiconductive nanoparticles (NPs) of copper sulphide, comprising the steps of: a) selecting a copper salt; b) growing a microorganism that tolerates the selected copper salt until it reaches its exponential or stationary phase; c) resuspending the sediment of the microorganism in a buffer solution of phosphate and treating with at least one of the selected copper salts until the microorganism acquires fluorescent characteristics; d) evaluating the production of the fluorescent, semi-conductive NPs of copper sulphide, exposing the bacterial cells to UV light (360 nm); and e) purifying the fluorescent, semiconductive NPs of copper sulphide.
CONTROLLED RELEASE SYSTEM COMPRISING A GAS OR VOLATILE ENCAPSULATED IN A POLYMERIC SUPPORT AND A MATRIX SYSTEM; METHOD OF PREPARATION SAID SYSTEM, AND THEIR USE APPLIED TO AGRIBUSINESS, FORESTRY, PHARMACEUTICALS, COSMETICS, AMONG OTHERS
Controlled release system wherein it comprises a polymeric support, a polymeric matrix, and encapsulated gases or volatiles; method for preparing said system wherein it comprises the steps of: (a) preparing a polymeric support; (b) encapsulating a gas or volatile; and (c) preparing a polymeric matrix and use of the gas or volatile controlled release system that it serves for the controlled release of gas or volatile in an agribusiness, forestry, pharmaceuticals, cosmetics, among others applications.
A01N 27/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des hydrocarbures
A01N 31/04 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques de l'oxygène ou du soufre l'atome d'oxygène ou de soufre étant lié à une chaîne latérale aliphatique d'un système cyclique carbocyclique
A01N 31/06 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques de l'oxygène ou du soufre l'atome d'oxygène ou de soufre étant lié directement à un système cyclique cycloaliphatique
28.
Use of compounds that selectively modulate astrocytic release of substances through hemichannels of connexins and pannexins, without influencing gap junctions, for the treatment of psychiatric disorders
Katholieke Universiteit Leuven, Ku Leuven R & D (Belgique)
Inventeur(s)
Stehberg Liberman, Jimmy
Leybaert Sinia, Luc Gilbert
Bultynck Demets, Geert Albert
Retamal Lucero, Mauricio Antonio
Gonzalez Nilo, Fernando Danilo
Abrégé
The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof used in the present invention comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering to a mammal or human a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also considered in the present invention. Examples are shown for connexin 43, connexin 30 and pannexin 1 hemichannel modulators shown not to affect gap junctions, in the form of both non peptide compounds and peptides which were tested in different models for psychiatric disorders, comprising PTSD, memory, anxiety and depression.
A01N 43/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques
The present invention is related to a system for handling and conditioning marine and brackish benthonic and demersal breeding fishes, allowing their reproduction and production of viable eggs in captivity, the system comprising at least one tank or farm unit, at least one shelter or farm subunit, at least one label system, and at least one subsystem for measuring, weighing, treating, controlling, and transferring the breeders; and a method of fish farming for benthonic and demersal breeding fishes, the method comprising the steps of (a) farming of breeders; and (b) reproduction, which comprises spawning and fertilization.
The present invention describes synthetic proteins (SP) based on dendrimers, which are fabricated by conjugating amino acid groups, or their functional groups, in different proportions, to the terminal group of a dendrimer. In addition to amino acid groups, or their functional groups, synthetic proteins based on dendrimers of the present invention can also comprise alcohol groups. The affinity of the terminal groups for particular ligands is determined according to the protein function that the synthetic protein is to mimic. In a particular embodiment, the functionalization with multiple different terminal groups grants biological properties to the synthetic protein based on dendrimers, allowing, among other functions, the transfection and effective release of drugs (particularly nucleic-acid based drugs) with minimal toxic effects to the target cells.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
31.
COMPOUNDS MODULATING ASTROCYTIC RELEASE OF SUBSTANCES THROUGH CONNEXINS AND PANNEXINS AND TREATMENT OF PSYCHIATRIC DISORDERS
KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D (Belgique)
Inventeur(s)
Stehberg Liberman, Jimmy
Leybaert Sinia, Luc Gilbert
Bultynck Demets, Geert Albert
Retamal Lucero, Mauricio Antonio
Gonzalez Nilo, Fernando Danilo
Abrégé
The present invention is related to the use of compounds or pharmaceutically acceptable salts thereof that modulate astrocytic release of substances through connexin and pannexin hemichannels, for the treatment of psychiatric disorders. Compounds or pharmaceutically acceptable salts thereof comprise any compound that differentially modulates, blocks, opens, inhibits, and/or activates connexin and/or pannexin hemichannels from astrocytes while not affecting gap junctions. The invention is also related to a method for treating psychiatric disorders, comprising administering a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof, that modulates astrocytic release of substances through connexin and pannexin hemichannels. Pharmaceutical compositions and a screening method are also provided. Examples are shown for connexin 43, connexin 30 and pannexin 1 hemichannel modulators shown not to affect gap junctions, which were tested in different models for psychiatric disorders, comprising PTSD, memory, anxiety and depression.